‌

US Patent 12065463 Compositions and methods for treating CNS disorders

Patent 12065463 was granted and assigned to SAGE Therapeutics on August, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

SAGE Therapeutics

0

Current Assignee

SAGE Therapeutics

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Albert Jean Robichaud0

Francesco G. Salituro0

Gabriel Martinez Botella0

Boyd L. Harrison0

Date of Patent

August 20, 2024

0

Patent Application Number

179718650

Date Filed

October 24, 2022

0

Patent Citations

US Patent 9365611 19-NOR neuroactive steroids and methods of use thereof

0

US Patent 9512165 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof

0

US Patent 9630986 Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same

0

US Patent 9725481 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof

0

US Patent 9765110 Neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same

0

US Patent 10246482 Neuroactive steroids, compositions, and uses thereof

0

US Patent 10577390 Compositions and methods for treating CNS disorders

0

US Patent 10857163 Compositions that preferentially potentiate subtypes of GABA

0

...

Patent Primary Examiner

Brenda L Coleman

0

CPC Code

0

0

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 12065463 Compositions and methods for treating CNS disorders

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool